FROM Katie Thomas
Can politics cure the high cost of drugs? EpiPens are the poster child for vast increases in the price of familiar medications. Many people carry them for emergency treatment of allergic reactions that can be life threatening. So, when the Mylan Company raised the price of two EpiPens from $100 $614 it made big news. Turns out, it's the tip of the iceberg. Drug prices are on the rise and desperately ill people are often those hit by bills they never expected. Other countries have established price controls for life-or-death medications, but America's system is so complex it defies understanding. Drug and insurance companies, hospitals and doctors engage in secret negotiations, while various middlemen get cuts of the action. And, who's paying for those expensive ads on TV? Patients. Are the presidential campaigns offering any realistic solutions?
Shoddy Practices at Big Drug Makers So-called "compounding pharmacies" regulated by the states have been taking heat since the recent outbreak of meningitis. Today's New York Times reports that one-third of the drug manufacturing industry overseen by the Food and Drug Administration is off line because of "quality issues." Katie Thomas covers the business of healthcare for the New York Times .
Venezuela spirals into economic and political chaos Venezuela, a country whose potential for prosperity is unmatched, finds itself on the verge of civil war. What sustains the repressive government? With time running out, guest host León Krauze looks at what the international community can do to pull the country from the edge of collapse.
Who's to blame for the opioid crisis? Some of the lawyers who took on Big Tobacco are now going after Big Pharma. It’s all about the deadly epidemic of opioid use. Are the drug companies to blame? What about the users? Later, on today’s Talking Point: making sense of Britain’s upset election.
The Trump agenda: where's the beef? President Trump says big things are happening. After celebrating a House bill on health care, he doesn’t yet have Senate agreement. With James Comey’s public testimony scheduled tomorrow, the President today tweeted his selection of a new FBI Director. Is the Chief Executive all style and no substance? Later, terror attacks in Iran and conflicting claims about who’s behind them.
Ex-FBI Director Comey tells his side of the story Today, former FBI Director James Comey came close to calling the President who fired him a liar. The White House denied the claim and called it insulting, but Republican Senators did not challenge Comey’s truthfulness. Many questions remain: did the President try to obstruct a federal investigation? Later, we’ll go behind the “velvet rope” for a look at 5-Star health care for the richest Americans.